Iovance Biotherapeutics (IOVA) announced the appointment of Corleen Roche as Chief Financial Officer, effective August 6th, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics downgraded to Sell from Neutral at Goldman Sachs
- H.C. Wainwright sees ‘impressive’ commercial data for Iovance’s Amtagvi
- Iovance Biotherapeutics announces real-world study data on Amtagvi
- Iovance Biotherapeutics Advances Phase 3 Study in Melanoma Treatment
- Iovance Biotherapeutics’ Lifileucel-Pembrolizumab Study: A Potential Game-Changer in Melanoma Treatment